Cidara Therapeutics (CDTX) Stock Soars After $339M BARDA Flu-Drug Deal – Is CD388 the Next Big Flu-Fighter?
Cidara Trading on Oct 3, 2025 On Friday morning Oct 3, CDTX was trading around $104 per share, up roughly 5.7% from Thursday’s close finviz.com. Trading volumes are high as investors digest the Oct 2 BARDA award news. (Finviz shows a sharp jump on Oct 2: GlobeNewswire’s BARDA release coincides with a ~5.7% stock bump finviz.com.) Cidara’s one-year chart is steeply upward – from around $10 a year ago to over $100 now (a nearly 900% one-year increase finviz.com). Most of that gain occurred since June, after positive Phase 2b results for CD388 and the $402M financing. CEO Jeffrey Stein noted on the Phase 3 dosing press release